Post-transplant lymphoproliferative disease (PTLD): Lymphokine production and PTLD

Springer Seminars in Immunopathology

Volumn 20, Issue 3-4, 1998, Pages 405-423

  Tosato, Giovanna ^a   Teruya Feldstein, Julie ^b   Setsuda, Joyce ^b   Pike, Sandra E ^a   Jones, Karen D ^a   Jaffe, Elaine S ^b  

^a CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; LYMPHOKINE; LYMPHOTOXIN; MEMBRANE PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

B LYMPHOCYTE; CELL IMMORTALIZATION; EPSTEIN BARR VIRUS; GRAFT REJECTION; HUMAN; LYMPHOPROLIFERATIVE DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; VIRUS INFECTION;

EID: 0031794913     PISSN: 03444325     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF00838052     Document Type: Review

References (176)

1. Miller G (1990) Epstein-Barr virus, biology, pathogenesis, and medical aspects. In: Fields B, Knipe D (eds) Virology. Raven Press, New York, pp 1921-1958
2. Straus SE, Cohen JI, Tosato G, Meier J (1993) NIH conference. Epstein-Barr virus infections: biology, pathogenesis, and management. Ann Intern Med 118:45
3. Rickinson AB, Lee SP, Steven NM (1996) Cytotoxic T lymphocyte responses to Epstein-Barr virus. Curr Opin Immunol 8:492
4. Masucci MG, Ernberg I (1994) Epstein-Barr virus: adaptation to a life within the immune system. Trends Microbiol 2:125
5. Tosato G, Taga K, Angiolillo AL, Sgadari C (1995) Epstein-Barr virus as an agent of haematological disease. In: Young N (eds) Clinical haematology. Viruses as agents of haematological disease. Bailliere Tindall, London, pp 165-199
6. Zutter MM, Martin PJ, Sale GE, Shulman HM, Fisher L, Thomas ED, Durnam DM (1988) Epstein-Barr virus lymphoproliferation after bone marrow transplantation. Blood 72:520
7. Swinnen LJ, Costanzo-Nordin MR, Fisher SG, O'Sullivan EJ, Johnson MR, Heroux AL, Dizikes GJ, Pifarre R, Fisher RI (1990) Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac-transplant recipients [see comments]. N Engl J Med 323:1723
8. Klein G (1994) Epstein-Barr virus strategy in normal and neoplastic B cells. Cell 77:791
9. Starzl TE, Nalesnik MA, Porter KA, et al (1984) Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy. Lancet 1:583
10. Nalesnik MA, Jaffe R, Starzl TE, Demetris AJ, Porter K, Burnham JA, Makowka L, Ho M, Locker J (1988) The pathology of posttransplant lymphoproliferative disorders occurring in the setting of cyclosporine A-prednisone immunosuppression. Am J Pathol 133:173
11. Heslop HE, Rooney CM (1997) Adoptive cellular immunotherapy for EBV lymphoproliferative disease. Immunol Rev 157:217
12. Lucas KG, Pollok KE, Emanuel DJ (1997) Post-transplant EBV induced lymphoproliferative disorders. Leuk Lymphoma 25:1
13. Nalesnik MA, Rao AS, Furukawa H, Pham S, Zeevi A, Fung JJ, Klein G, Gritsch HA, Elder E, Whiteside TL, Starzl TE (1997) Autologous lymphokine-activated killer cell therapy of Epstein-Barr virus-positive and -negative lymphoproliferative disorders arising in organ transplant recipients. Transplantation 63:1200
14. Randhawa PS, Whiteside TL, Zeevi A, Elder EM, Rao AS, Demetris AJ, Weng X, Valdivia LA, Rakela J, Nalesnik MA (1998) Effects of immunotherapy on experimental immunodeficiency-related lymphoproliferative disease. Transplantation 65:264
15. Swinnen LJ (1997) Treatment of organ transplant-related lymphoma. Hematol Oncol Clin North Am 11:963
16. Nalesnik MA, Starzl TE (1994) Epstein-Barr virus, infectious mononucleosis, and posttransplant lymphoproliferative disorders. Transplant Sci 4:61
17. Nalesnik MA (1996) Posttransplantation lymphoproliferative disorders (PTLD): current perspectives. Semin Thorac Cardiovasc Surg 8:139
18. Wu TT, Swerdlow SH, Locker J, Bahler D, Randhawa P, Yunis EJ, Dickman PS, Nalesnik MA (1996) Recurrent Epstein-Barr virus-associated lesions in organ transplant recipients. Hum Pathol 27:157
19. Doherty PC, Tripp RA, Hamilton-Easton AM, Cardin RD, Woodland DL, Blackman MA (1997) Tuning into immunological dissonance: an experimental model for infectious mononucleosis [sec comments]. Curr Opin Immunol 9:477
20. Andersson J (1996) Clinical and immunological considerations in Epstein-Barr virus-associated diseases. Scand J Infect Dis [Suppl] 100:72
21. Tripp RA, Hamilton-Easton AM, Cardin RD, Nguyen P, Behm FG, Woodland DL, Doherty PC, Blackman MA (1997) Pathogenesis of an infectious mononucleosis-like disease induced by a murine gamma-herpesvirus: role for a viral superantigen? J Exp Med 185:1641
22. Swerdlow SH (1997) Classification of the posttransplant lymphoproliferative disorders: from the past to the present. Semin Diagn Pathol 14:2
23. Harris NL, Ferry JA, Swerdlow SH (1997) Posttransplant lymphoproliferative disorders: summary of Society for Hematopathology Workshop. Semin Diagn Pathol 14:8
24. Randhawa PS, Markin RS, Starzl TE, Demetris AJ (1990) Epstein-Barr virus-associated syndromes in immunosuppressed liver transplant recipients. Clinical profile and recognition on routine allograft biopsy. Am J Surg Pathol 14:538
25. Tosato G (1987) The Epstein-Barr virus and the immune system. Adv Cancer Res 49:75
26. Randhawa PS, Demetris AJ, Nalesnik MA (1994) The potential role of cytokines in the pathogenesis of Epstein-Barr virus associated post-transplant lymphoproliferative disease. Leuk Lymphoma 15:383
27. Randhawa PS, Pietrzak B, Nalesnik MA, Demetris AJ, Locker J (1997) Subcutaneous implantation of human post-transplant lymphoproliferative disease lesions in SCID mice. Hematol Oncol 15:39
28. Tosato G, Gerrard TL, Goldman NG, Pike SE (1988) Stimulation of EBV-activated human B cells by monocytes and monocyte products. Role of IFN-beta 2/B cell stimulatory factor 2/IL-6. J Immunol 140:4329
29. Tosato G, Pike SE (1989) A monocyte-derived B cell growth factor is IFN-beta 2/BSF-2/IL-6. Ann N Y Acad Sci 557:181, discussion 190
30. Tosato G, Seamon KB, Goldman ND, Sehgal PB, May LT, Washington GC, Jones KD, Pike SE (1988) Monocyte-derived human B-cell growth factor identified as interferon-beta 2 (BSF-2, IL-6). Science 239:502
31. Gordon J, Ley SC, Melamed MD, Aman P, Hughes-Jones NC (1984) Soluble factor requirements for the autostimulatory growth of B lymphoblasts immortalized by Epstein-Barr virus. J Exp Med 159:1554
32. Blazar BA, Sutton LM, Strome M (1983) Self-stimulating growth factor production by B-cell lines derived from Burkitt's lymphomas and other lines transformed in vitro by Epstein-Barr virus. Cancer Res 43:4562
33. Su IJ, Chen JY (1997) The role of Epstein-Barr virus in lymphoid malignancies. Crit Rev Oncol Hematol 26:25
34. Oppenheim J, Fujiwara H (1996) The role of cytokines in cancer. Cytokine Growth Factor Rev 7:279
35. Liebowitz D, Kieff E (1993) Epstein-Barr virus. In: Roizman B, Whitley R, Lopez C (eds) The human herpesvirus. Raven Press New York, p 107
36. Hammerschmidt W, Sugden B (1989) Genetic analysis of immortalizing functions of Epstein-Barr virus in human B lymphocytes. Nature 340:393
37. Baichwal VR, Sugden B (1988) Transformation of Balb 3T3 cells by the BNLF-1 gene of Epstein-Barr virus. Oncogene 2:461
38. Moorthy RK, Thorley-Lawson DA (1993) All three domains of the Epstein-Barr virus-encoded latent membrane protein LMP-1 are required for transformation of rat-1 fibroblasts. J Virol 67:1638
39. Kaye KM, Izumi KM, Mosialos G, Kieff E (1995) The Epstein-Barr virus LMP1 cytoplasmic carboxy terminus is essential for B-lymphocyte transformation; fibroblast cocultivation complements a critical function within the terminal 155 residues. J Virol 69:675
40. Kaye KM, Devergne O, Harada JN, Izumi KM, Yalamanchili R, Kieff E, Mosialos G (1996) Tumor necrosis factor receptor associated factor 2 is a mediator of NF-kappa B activation by latent infection membrane protein 1, the Epstein-Barr virus transforming protein. Proc Natl Acad Sci USA 93:11085
41. Mosialos G, Birkenbach M, Yalamanchili R, VanArsdale T, Ware C, Kieff E (1995) The Epstein-Barr virus transforming protein LMP1 engages signaling proteins for the tumor necrosis factor receptor family. Cell 80:389
42. Devergne O, Hatzivassiliou E, Izumi KM, Kaye KM, Kleijnen MF, Kieff E, Mosialos G (1996) Association of TRAF1, TRAF2, and TRAF3 with an Epstein-Barr virus LMP1 domain important for B-lymphocyte transformation: role in NF-kappaB activation. Mol Cell Biol 16:7098
43. Rothe M, Wong SC, Henzel WJ, Goeddel DV (1994) A novel family of putative signal transducers associated with the cytoplasmic domain of the 75 kDa tumor necrosis factor receptor. Cell 78:681
44. Saeland S, Duvert V, Moreau I, Banchereau J (1993) Human B cell precursors proliferate and express CD23 after CD40 ligation. J Exp Med 178:113
45. Eliopoulos AG, Dawson CW, Mosialos G, Floettmann JE, Rowe M, Armitage RJ, Dawson J, Zapata JM, Kerr DJ, Wakelam MJ, Reed JC, Kieff E, Young LS (1996) CD40-induced growth inhibition in epithelial cells is mimicked by Epstein-Barr Virus-encoded LMP1: involvement of TRAF3 as a common mediator. Oncogene 13:2243
46. Banchereau J, Bazan F, Blanchard D, Briere F, Galizzi JP, Kooten C van, Liu YJ, Rousset F, Saeland S (1994) The CD40 antigen and its ligand. Annu Rev Immunol 12:881
47. Galibert L, Durand I, Banchereau J, Rousset F (1994) CD40-activated surface IgD-positive lymphocytes constitute the long term IL-4-dependent proliferating B cell pool. J Immunol 152:22
48. Hennessy K, Fennewald S, Hummel M, Cole T, Kieff E (1984) A membrane protein encoded by Epstein-Barr virus in latent growth-transforming infection. Proc Natl Acad Sci USA 81:7207
49. Tartaglia LA, Goeddel DV (1992) Tumor necrosis factor receptor signaling. A dominant negative mutation suppresses the activation of the 55-kDa tumor necrosis factor receptor. J Biol Chem 267:4304
50. Mitchell T, Sugden B (1995) Stimulation of NF-kappa B-mediated transcription by mutant derivatives of the latent membrane protein of Epstein-Barr virus. J Virol 69:2968
51. Huen DS, Henderson SA, Croom-Carter D, Rowe M (1995) The Epstein-Barr virus latent membrane protein-1 (LMP1) mediates activation of NF-kappa B and cell surface phenotype via two effector regions in its carboxy-terminal cytoplasmic domain. Oncogene 10:549
52. Siebenlist U, Franzoso G, Brown K (1994) Structure, regulation and function of NF-kappa B. Annu Rev Cell Biol 10:405
53. Lion HC, Baltimore D (1993) Regulation of the NF-kappa B/rel transcription factor and I kappa B inhibitor system. Curr Opin Cell Biol 5:477
54. Scala G, Kuang YD, Hall RE, Muchmore AV, Oppenheim JJ (1984) Accessory cell function of human B cells. I. Production of both interleukin 1-like activity and an interleukin 1 inhibitory factor by an EBV-transformed human B cell line. J Exp Med 159:1637
55. Matsushima K, Tosato G, Benjamin D, Oppenheim JJ (1985) B-cell-derived interleukin-1 (IL-1)-like factor. II. Sources, effects, and biochemical properties. Cell Immunol 94:418
56. Vandenabeele P, Jayaram B, Devos R, Shaw A, Fiers W (1988) Interleukin 1-α acts as an autocrine growth factor for RPMI 1788, an Epstein-Barr virus-transformed human B cell line. Eur J Immunol 18:1027
57. Vandenabeele P, Declercq W, Libert C, Fiers W (1990) Development of a simple, sensitive and specific bioassay for interleukin-1 based on the proliferation of RPMI 1788 cells. Comparison with other bioassays for IL-1. J Immunol Methods 135:25
58. Acres RB, Larsen A, Gillis S, Conlon PJ (1987) Production of IL-1 alpha and IL-1 beta by clones of EBV transformed, human B cells. Mol Immunol 24:479
59. Matsushima K, Kuang YD, Tosato G, Hopkins SJ, Oppenheim JJ (1985) B-cell-derived interleukin 1 (IL-1)-like factor. I. Relationship of production of IL-1-like factor to accessory cell function of Epstein-Barr virus-transformed human B-lymphoblast lines. Cell Immunol 94:406
60. Gordon J, Guy G, Walker L, Nathan P, Exley R, Clemens M (1986) Autocrine growth of human B lymphocytes: maintained response to autostimulatory factors is the special feature of immortalization by Epstein-Barr virus - a hypothesis. Med Oncol Tumor Pharmacother 3:269
61. Blazar BA, Murphy AM (1990) Induction of B cell responsiveness to growth factors by Epstein-Barr virus conversion: comparison of endogenous factors and interleukin-1. Clin Exp Immunol 80:62
62. Tosato G, Gerrard TL, Goldman NG, Pike SE (1988) Stimulation of EBV-activated human B cells by monocytes and monocyte products. Role of IFN-beta 2/B cell stimulatory factor 2/IL-6. J Immunol 140:4329
63. Gerrard TL, Volkman DJ (1985) IL 1-like activity in antigen-presenting human B cell lines. J Immunol 135:3217
64. Rimsky L, Wakasugi H, Ferrara P, Robin P, Capdevielle J, Tursz T, Fradelizi D, Bertoglio J (1986) Purification to homogeneity and NH2-terminal amino acid sequence of a novel interleukin 1 species derived from a human B cell line. J Immunol 136:3304
65. Teshigawara K, Maeda M, Nishino K, Nikaido T, Uchiyama T, Tsudo M, Wano Y, Yodoi J (1985) Adult T leukemia cells produce a lymphokine that augments interleukin 2 receptor expression. J Mol Cell Immunol 2:17
66. Wakasugi N, Tagaya Y, Wakasugi H, Mitsui A, Maeda M, Yodoi J, Tursz T (1990) Adult T-cell leukemia-derived factor/thioredoxin, produced by both human T-lymphotropic virus type I- and Epstein-Barr virus-transformed lymphocytes, acts as an autocrine growth factor and synergizes with interleukin 1 and interleukin 2. Proc Natl Acad Sci USA 87:8282
67. Linde A, Andersson B, Svenson SB, et al (1992) Serum levels of lymphokines and soluble cellular receptors in primary Epstein-Barr virus infection and in patients with chronic fatigue syndrome. J Infect Dis 165:994
68. Foss HD, Herbst H, Hummel M, Araujo I, Latza U, Rancso C, Dallenbach F, Stein H (1994) Patterns of cytokine gene expression in infectious mononucleosis. Blood 83:707
69. Birkeland SA, Hamilton-Dutoit S, Sandvej K, Andersen HM, Bendtzen K, Moller B, Jorgensen KA (1995) EBV-induced post-transplant lymphoproliferative disorder (PTLD). Transplant Proc 27:3467
70. Banchereau J, Paoli P de, Valle A, Garcia E, Rousset F (1991) Long-term human B cell lines dependent on interleukin-4 and antibody to CD40. Science 251:70
71. Favrot MC, Maritaz O, Suzuki T, Cooper M, Philip I, Philip T, Lenoir G (1986) EBV-negative and -positive Burkitt cell lines variably express receptors for B-cell activation and differentiation. Int J Cancer 38:901
72. Rousset F, Billaud M, Blanchard D, Figdor C, Lenoir GM, Spits H, De Vries JE (1989) IL-4 induces LFA-1 and LFA-3 expression on Burkitt's lymphoma cell lines. Requirement of additional activation by phorhol myristate acetate for induction of homotypic cell adhesions. J Immunol 143:1490
73. Gauchat JF, Gascan H, Waal Malefyt R de, Vries JE de (1992) Regulation of germ-line epsilon transcription and induction of epsilon switching in cloned EBV-transformed and malignant human B cell lines by cytokines and CD4+ T cells. J Immunol 148:2291
74. Bende RJ, Jochems GJ, Frame TH, Klein MR, Eijk RV van, Lier RA van, Zeijlemaker WP (1992) Effects of IL-4, IL-5, and IL-6 on growth and immunoglobulin production of Epstein-Barr virus-infected human B cells. Cell Immunol 143:310
75. Richter W, Eiermann TH, Scherbaum WA (1990) Effect of cytokines on proliferation of Epstein Barr virus-transformed B lymphocytes. Hybridoma 9:1
76. Defrance T, Fluckiger AC, Rossi JF, Magaud JP, Sotto JJ, Banchereau J (1992) Antiproliferative effects of interleukin-4 on freshly isolated non-Hodgkin malignant B-lymphoma cells. Blood 79:990
77. Taylor CW, Grogan TM, Salmon SE (1990) Effects of interleukin-4 on the in vitro growth of human lymphoid and plasma cell neoplasms. Blood 75:1114
78. Shields JG, Kotowicz K, Callard RE (1992) Interleukin-4 stimulates immunoglobulin secretion by Epstein-Barr virus (EBV)-activated tonsillar B cells, and by EBV-transformed lymphoblastoid B cell lines without increasing cell division. Int J Clin Lab Res 22:95
79. Thyphronitis G, Tsokos GC, June CH, Levine AD, Finkelman FD (1989) IgE secretion by Epstein-Barr virus-infected purified human B lymphocytes is stimulated by interleukin 4 and suppressed by interferon gamma. Proc Natl Acad Sci USA 86:5580
80. Thyphronitis G, Max EE, Finkelman FD (1991) Generation and cloning of stable human IgE-secreting cells that have rearranged the C epsilon gene. J Immunol 146:1496
81. Shapira SK, Jabara HH, Thienes CP, Ahern DJ, Vercelli D, Gould HJ, Geha RS (1991) Deletional switch recombination occurs in interleukin-4-induced isotype switching to IgE expression by human B cells. Proc Natl Acad Sci USA 88:7528
82. Jabara HH, Ahem DJ, Vercelli D, Geha RS (1991) Hydrocortisone and IL-4 induce IgE isotype switching in human B cells. J Immunol 147:1557
83. Mills FC, Thyphronitis G, Finkelman FD, Max EE (1992) Ig mu-epsilon isotype switch in IL-4-treated human B lymphoblastoid cells. Evidence for a sequential switch. J Immunol 149:1075
84. Ohnishi E, Iwata T, Inouye S, Kurata T, Sairenji T (1997) Interleukin-4 production in Epstein-Barr virus-transformed B cell lines from peripheral mononuclear cells of patients with atopic dermatitis. J Interferon Cytokine Res 17:597
85. Fior R, Vita N, Raphael M, et al (1994) Interleukin-13 gene expression by malignant and EBV-transformed human B lymphocytes. Eur Cytokine Netw 5:593
86. Waal Malefyt R de, Abrams JS, Zurawski SM, Lecron JC, Mohan-Peterson S, Sanjanwala B, Bennett B, Silver J, Vries JE de, Yssel H (1995) Differential regulation of IL-13 and IL-4 production by human CD8+ and CD4+ Th0, Th1 and Th2 T cell clones and EBV-transformed B cells. Int Immunol 7:1405
87. Prabhu A, Warwick M, Mathur A (1996) Decreased levels of circulating IFN-alpha and increased sCD23 in patients with acute infectious mononucleosis. Viral Immunol 9:45
88. Burke G, Cirocco R, Hansley G, Reddy R, Jeffers L, Schiff E (1991) The rapid development of a fatal disseminated B cell lymphoma following liver transplantation: serial changes in levels of soluble IL-2 and IL-4. Transplantation 53:1148
89. Mathur A, Kamat DM, Filipovich AH, Steinbuch M, Shapiro RS (1994) Immunoregulatory abnormalities in patients with Epstein-Barr virus-associated B cell lymphoproliferative disorders. Transplantation 57:1042
90. Paul CC, Keller JR, Armpriester JM, Baumann MA (1990) Epstein-Barr virus transformed B lymphocytes produce interleukin-5. Blood 75:1400
91. Chang H, Jamal N, Wang XH, Minden MD, Messner HA (1992) Constitutive production of the interleukins IL-5 and IL-6 by the lymphoma cell line OCI-Ly 17 derived from a patient with malignant lymphoma and hypereosinophilia. Leuk Lymphoma 8:97
92. Baumann MA, Paul CC (1992) Interleukin-5 is an autocrine growth factor for Epstein-Barr virus-transformed B lymphocytes. Blood 79:1763
93. Baumann MA, Paul CC (1997) Interleukin-5 and human B lymphocytes. Methods 11:88
94. Samoszuk M, Nansen L (1990) Detection of interleukin-5 messenger RNA in Reed-Sternberg cells of Hodgkin's disease with eosinophilia. Blood 75:13
95. Weiss LM (1992) Gene analysis and Epstein-Barr viral genome studies of Hodgkin's disease. Int Rev Exp Pathol 33:165
96. Samoszuk M, Ravel J, Ramzi E (1992) Epstein-Barr virus and interleukin-5 mRNA in acquired immunodeficiency syndrome-related lymphomas with eosinophilia. Hum Pathol 23:1355
97. Tosato G, Tanner J, Jones KD, Revel M, Pike SE (1990) Identification of interleukin-6 as an autocrine growth factor for Epstein-Barr virus-immortalized B cells. J Virol 64:3033
98. Hutchins D, Cohen BB, Steel CM (1990) Production and regulation of interleukin 6 in human B lymphoid cells. Eur J Immunol 20:961
99. Yokoi T, Miyawaki T, Yachie A, Kato K, Kasahara Y, Taniguchi N (1990) Epstein-Barr virus-immortalized B cells produce IL-6 as an autocrine growth factor. Immunology 70:100
100. Klein SC, Jucker M, Abts H, Tesch H (1995) IL6 and IL6 receptor expression in Burkitt's lymphoma and lymphoblastoid cell lines: promotion of IL6 receptor expression by EBV. Hematol Oncol 13:121
101. Taga T, Kawanishi Y, Hardy RR, Hirano T, Kishimoto T (1987) Receptors for B cell stimulatory factor 2. Quantitation, specificity, distribution, and regulation of their expression. J Exp Med 166:967
102. Tanner J, Tosato G (1991) Impairment of natural killer functions by interleukin 6 increases lymphoblastoid cell tumorigenicity in athymic mice. J Clin Invest 88:239
103. Scala G, Quinto I, Ruocco MR, Arcucci A, Mallardo M, Caretto P, Forni G, Venuta S (1990) Expression of an exogenous interleukin 6 gene in human Epstein Barr virus B cells confers growth advantage and in vivo tumorigenicity. J Exp Med 172:61
104. Folkman J (1992) The role of angiogenesis in tumor growth. Semin Cancer Biol 3:65
105. Tosato G, Jones K, Breinig MK, McWilliams HP, McKnight JL (1993) Interleukin-6 production in posttransplant lymphoproliferative disease. J Clin Invest 91:2806
106. Jones K, Rivera C, Sgadari C, Franklin J, Max EE, Bhatia K, Tosato G (1995) Infection of human endothelial cells with Epstein-Barr virus. J Exp Med 182:1213
107. Moore KW, O'Garra A, Waal Malefyt R de, Vieira P, Mosmann TR (1993) Interleukin-10. Annu Rev Immunol 11:165
108. Vieira P, Waal-Malefyt R de, Dang MN, Johnson KE, Kastelein R, Fiorentino DF, Vries JE de, Roncarolo MG, Mosmann TR, Moore KW (1991) Isolation and expression of human cytokine synthesis inhihitory factor cDNA clones: homology to Epstein-Barr virus open reading frame BCRFI. Proc Natl Acad Sci USA 88:1172
109. Hsu DH, Waal Malefyt R de, Fiorentino DF, Dang MN, Vieira P, Vries J de, Spits H, Mosmann TR, Moore KW (1990) Expression of interltukin-10 activity by Epstein-Barr virus protein BCRF1. Science 250:830
110. Hudson GS, Bankier AT, Satchwell SC, Barrell BG (1985) The short unique region of the B95-8 Epstein-Barr virus genome. Virology 147:81
111. Waal Malefyt R de, Haanen J, Spits H, Roncarolo MG, Velde A te, Figdor C, Johnson K, Kastelein R, Yssel H, Vries JE de (1991) Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression. J Exp Med 174:915
112. Rousset F, Garcia E, Defrance T, Peronne C, Vezzio N, Hsu DH, Kastelein R, Moore KW, Banchereau J (1992) Interleukin 10 is a potent growth and differentiation factor for activated human B lymphocytes. Proc Natl Acad Sci USA 89:1890-1893
113. Burdin N, Peronne C, Banchereau J, Rousset F (1993) Epstein-Barr virus transformation induces B lymphocytes to produce human interleukin 10. J Exp Med 177:295
114. Levy Y, Brouet JC (1994) Interleukin-10 prevents spontaneous death of germinal center B cells by induction of the bcl-2 protein. J Clin Invest 93:424
115. Beatty PR, Krams SM, Martinez OM (1997) Involvement of IL-10 in the autonomous growth of EBV-transformed B cell lines. J Immunol 158:4045
116. Baiocchi RA, Ross ME, Tan JC, et al (1995) Lymphomagenesis in the SCID-hu mouse involves abundant production of human interleukin-10. Blood 85:1063
117. Stewart JP, Behm FG, Arrand JR, Rooney CM (1994) Differential expression of viral and human interleukin-10 (IL-10) by primary B cell tumors and B cell lines. Virology 200:724
118. Miyazaki I, Cheung RK, Dosch HM (1993) Viral interleukin 10 is critical for the induction of B cell growth transformation by Epstein-Barr virus. J Exp Med 178:439
119. Swaminathan S, Hesselton R, Sullivan J, Kieff E (1993) Epstein-Barr virus recombinants with specifically mutated BCRFI genes. J Virol 67:7406
120. Stuart AD, Stewart JP, Arrand JR, Mackett M (1995) The Epstein-Barr virus encoded cytokine viral interleukin-10 enhances transformation of human B lymphocytes. Oncogene 11:1711
121. Taga K, Chretien J, Chemey B, Diaz L, Brown M, Tosato G (1994) Interleukin-10 inhibits apoptotic cell death in infectious mononucleosis T cells. J Clin Invest 94:251
122. Taga K, Tosato G (1992) IL-10 inhibits human T cell proliferation and IL-2 production. J Immunol 148:1143
123. Lotz M, Tsoukas CD, Fong S, Carson DA, Vaughan JH (1985) Regulation of Epstein-Barr virus infection by recombinant interferons. Selected sensitivity to interferon-γ. Eur J Immunol 15:520
124. Taga K, Cherney B, Tosato G (1993) IL-10 inhibits apoptotic cell death in human T cells starved of IL-2. Int Immunol 5:1599
125. Taga H, Taga K, Wang F, Chretien J, Tosato G (1995) Human and viral interleukin-10 in acute Epstein-Barr virus-induced infectious mononucleosis. J Infect Dis 171:1347
126. Kanegane H, Wakiguchi H, Kanegane C, Kurashige T, Tosato G (1997) Viral interleukin-10 in chronic active Epstein-Barr virus infection. J Infect Dis 176:254
127. Birkeland SA, Bendtzen K (1996) Interleukin-10 and Epstein-Barr virus-induced posttransplant lymphoproliferative disorder [letter]. Transplantation 61:1425
128. Kobayashi M, Fitz L, Ryan M, Hewick RM, Clark SC, Chan S, Loudon R, Sherman F, Perussia B, Trinchieri G (1989) Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes. J Exp Med 170:827
129. Stern AS, Podlaski FJ, Hulmes JD, et al (1990) Purification to homogeneity and partial characterization of cytotoxic lymphocyte maturation factor from human B-lymphoblastoid cells. Proc Natl Acad Sci USA 87:6808
130. Gubler U, Chua AO, Schoenhaut DS, et al (1991) Coexpression of two distinct genes is required to generate secreted bioactive cytotoxic lymphocyte maturation factor. Proc Natl Acad Sci USA 88:4143
131. Wolf SF, Temple PA, Kobayashi M, et al (1991) Cloning of cDNA for natural killer cell stimulatory factor, a heterodimeric cytokine with multiple biologic effects on T and natural killer cells. J Immunol 146:3074
132. D'Andrea A, Rengaraju M, Valiante NM, et al (1992) Production of natural killer cell stimulatory factor (interleukin 12) by peripheral blood mononuclear cells. J Exp Med 176:1387
133. Gately MK, Brunda MJ (1995) Interleukin-12: a pivotal regulator of cell-mediated immunity. Cancer Treat Res 80:341
134. Chan SH, Kobayashi M, Santoli D, Perussia B, Trinchieri G (1992) Mechanisms of IFN-gamma induction by natural killer cell stimulatory factor (NKSF/IL-12). Role of transcription and mRNA stability in the synergistic interaction between NKSF and IL-2. J Immunol 148:92
135. Gately MK, Warrier RR, Honasoge S, Carvajal DM, Faherty DA, Connaughton SE, Anderson TD, Sarmiento U, Hubbard BR, Murphy M (1994) Administration of recombinant IL-12 to normal mice enhances cytolytic lymphocyte activity and induces production of IFN-gamma in vivo. Int Immunol 6:157
136. Benjamin D, Sharma V, Kubin M, Klein JL, Sartori A, Holliday J, Trinchieri G (1996) IL-12 expression in AIDS-related lymphoma B cell lines. J Immunol 156:1626
137. Trinchieri G (1995) Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity. Annu Rev Immunol 13:251
138. Chizzonite R, Truitt T, Desai BB, Nunes P, Podlaski FJ, Stern AS, Gately MK (1992) IL-12 receptor. I. Characterization of the receptor on phytohemagglutinin-activated human lymphoblasts. J Immunol 148:3117
139. Chua AO, Chizzonite R, Desai BB, et al (1994) Expression cloning of a human IL-12 receptor component. A new member of the cytokine receptor superfamily with strong homology to gp130. J Immunol 153:128
140. Rogge L, Barberis-Maino L, Biffi M, Passini N, Presky DH, Gubler U, Sinigaglia F (1997) Selective expression of an interleukin-12 receptor component by human T helper 1 cells. J Exp Med 185:825
141. Prrsky DH, Yang H, Minetti LJ, Chua AO, Nabavi N, Wu CY, Gately MK, Gubler U (1996) A functional interleukin 12 receptor complex is composed of two beta-type cytokine receptor subunits. Proc Natl Acad Sci USA 93:14002
142. Devergne O, Hummel M, Koeppen H, Le Beau MM, Nathanson EC, Kieff E, Birkenhach M (1996) A novel interleukin-12 p40-related protein induced by latent Epstein-Barr virus infection in B lymphocytes [published erratum appears in J Virol (1996) 70:2678]. J Virol 70:1143
143. Devergne O, Birkenbach M, Kieff E (1997) Epstein-Barr virus-induced gene 3 and the p35 subunit of interltukin 12 form a novel heterodimeric hematopoietin. Proc Natl Acad Sci USA 94:12041
144. Goeddel DV, Aggarwal BB, Gray PW, et al (1986) Tumor necrosis factors: gene structure and biological activities. Cold Spring Harb Symp Quant Biol 51:597-609
145. Tartaglia LA, Ayres TM, Wong GH, Goeddel DV (1993) A novel domain within the 55 kd TNF receptor signals cell death. Cell 74:845
146. Eck MJ, Ultsch M, Rinderknecht E, Vos AM de, Sprang SR (1992) The structure of human lymphotoxin (tumor necrosis factor-beta) at 1.9-A resolution. J Biol Chem 267:2119
147. Jones EY, Stuart DI, Walker NP (1989) Structure of tumour necrosis factor. Nature 338:225
148. Banner DW, D'Arcy A, Janes W, Gentz K, Schoenfeld HJ, Broger C, Loetscher H, Lesslauer W (1993) Crystal structure of the soluble human 55 kd TNF receptor-human TNK beta complex: implications for TNF receptor activation. Cell 73:431
149. Smith CA, Farrah T, Goodwill RG (1994) The TNF receptor superfamily of cellular and viral proteins: activation, costimulation, and death. Cell 76:959
150. Aggarwal BB, Moffat B, Harkins RN (1984) Human lymphotoxin. Production by a lymphoblastoid cell line, purification, and initial characterization. J Biol Chem 259:686
151. Aggarwal BB, Henzel WJ, Moffat B, Kohr WJ, Harkins RN (1985) Primary structure of human lymphotoxin derived from 1788 lymphoblastoid cell line. J Biol Chem 260:2334
152. Estrov Z, Kurzrock R, Pocsik E, Pathak S, Kantarjian HM, Zipf TF, Harris D, Talpaz M, Aggarwal BB (1993) Lymphotoxin is an autocrine growth factor for Epstein-Barr virus-infected B cell lines. J Exp Med 177:763
153. Gibbons DL, Rowe M, Cope AP, Feldmann M, Brennan FM (1994) Lymphotoxin acts as an autocrine growth factor for Epstein-Barr virus-transformed B cells and differentiated Burkitt lymphoma cell lines. Eur J Imnumol 24:1879
154. Klein SC, Kube D, Abts H, Diehl V, Tesch H (1996) Promotion of IL8, IL10, TNF alpha and TNF beta production by EBV infection. Leuk Res 20:633
155. Roncella S, Baldi L, Cutrona G, Viale M, Rizzo F, Gasco M, Ferranni M, Pisloia V (1995) Production of inflammatory cytokines by Epstein-Barr virus (EBV)-infected lymphoblastoid cell lines spontaneously originated from the peripheral blood of patients with human immunodeficiency virus (HIV) infection. Clin Imnumol Immunopathol 77:162
156. Altomonte M, Pucillo C, Damante G, Maio M (1993) Cross-linking of HLA class II antigens modulates the release of tumor necrosis factor-alpha by the EBV-B lymphohlastoid cell line JY. J Immunol 151:5115
157. Altomonte M, Montagner R, Pucillo C, Maio M (1996) Triggering of target of an antiproliferative antibody-1 (TAPA-1/CD81) up-regulates the release of tumour necrosis factor-alpha by the EBV-B lymphohlastoid cell line JY. Scand J Immunol 43:367
158. Di Girolamo N, Visvanathan K, Lloyd A, Wakefield D (1997) Expression of TNF-alpha by human plasma cells in chronic inflammation. J Leukoc Biol 61:667
159. Roberts AB, Thompson NL, Heine U, Flanders C, Sporn MB (1988) Transforming growth factor-beta: possible roles in carcinogenesis. Br J Cancer 57:594
160. Kein JH, Taylor AS, Delsing GA, Roberts AB, Sporn MB, Fauci AS (1989) Further studies of the role of transforming growth factor-beta in human B cell function. J Immunol 143:1868
161. Altiok A, Di Renzo L, Altoik E (1994) Influence of transforming growth factor-beta (TGF-beta) on the immunoglobulin production by EBV-infected B cell cultures. Immunol Lett 43:199
162. Altiok A, Jadersten M, Magyarlaki T, Klein E (1994) Biphasic effect of transforming growth factor-beta on Epstein-Barr virus-induced activation of human tonsillar B cells. Immunol Lett 40:111
163. Chaouchi N, Arvanitakis L, Auffredou MT, Blanchard DA, Vazquez A, Sharma S (1995) Characterization of transforming growth factor-beta 1 induced apoptosis in normal human B cells and lymphoma B cell lines. Oncogene 11:1615
164. Arvanitakis L, Yaseen N, Sharma S (1995) Latent membrane protein-1 induces cyclin D2 expression, pRb hyperphosphorylation, and loss of TGF-bela 1-mediated growth inhibition in EBV-positive B cells. J Immunol 155:1047
165. Kumar A, Rogers T, Maizel A, Sharma S (1991) Loss of transforming growth factor beta 1 receptors and its effects on the growth of EBV-transformed human B cells. J Immunol 147:998
166. Altiok A, Bejarano MT, Ruscetti F, Altiok E, Klein G, Klein E (1991) Effect of transforming growth factor-beta 1 and -beta 2 on the proliferation of Burkitt lymphoma and lymphoblastoid cell lines. Growth Factors 4:117
167. Renzo L di, Altiok A, Klein G, Klein E (1994) Endogenous TGF-beta contributes to the induction of the EBV lytic cycle in two Burkitt lymphoma cell lines. Int J Cancer 57:914
168. Cayrol C, Flemington EK (1995) Identification of cellular target genes of the Epstein-Barr virus transactivalor Zta: activation of transforming growth factor beta igh3 (TGF-beta igh3) and TGE-beta 1. J Virol 69:4206
169. Andersson J, Ahrams J, Bjork L, Funa K, Litton M, Agren K, Andersson U (1994) Concomitant in vivo production of 19 different cytokines in human tonsils. Immunology 83:16
170. Angiolillo AL, Sgadari C, Taub DD, Liao F, Farber JM, Maheshwari S, Kleinman HK, Reaman GH, Tosato G (1995) Human interferon-inducible protein 10 is a potent inhibitor of angiogenesis in vivo. J Exp Med 182:155
171. Sgadari C, Angiolillo AL, Cherney BW, Pike SE, Farber JM, Koniaris LG, Vanguri P, Burd PR, Sheikh N, Gupta G, Teruya-Feldstein J, Tosato G (1996) Interferon-inducible protein-10 identified as a mediator of tumor necrosis in vivo. Proc Natl Acad Sci USA 93:13791
172. Sgadari C, Farber JM, Angiolillo AL, Liao F, Teruya-Feldstein J, Burd PR, Yao L, Gupta G, Kanegane C, Tosato G (1997) Mig, the monokine induced by
173. Sgadari C, Angiolillo AL, Tosato G (1996) Inhibition of angiogenesis by interleukin-12 is mediated by the interferon-inducible protein 10. Blood 87:3877
174. Strieter RM, Polverini PJ, Arenberg DA, Kunkel SL (1995) The role of CXC chemokines as regulators of angiogenesis. Shock 4:155
175. Stricter RM, Polverini PJ, Kunkel SL, et al (1995) The functional role of the ELR motif in CXC chemokine-mediated angiogenesis. J Biol Chem 270:27348
176. Teruya-Feldstein J, Jaffe ES, Burd PR, Kanegane H, Kingma DW, Wilson WH, Longo DL, Tosato G (1997) The role of Mig, the monokine induced by interferon-gamma, and IP-10, the interferon-gamma-inducible protein-10, in tissue necrosis and vascular damage associated with Epstein-Barr virus-positive lymphoproliferative disease. Blood 90:4099